Physician profile
Nancy Baratta
NPI 1578590121
$5,193.95
in general payments reported to CMS, 2019-2025
28 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,884 · 2022: $1,126 · 2023: $1,105 · 2024: $636 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.75 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,221.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $712.44 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $474.90 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $326.78 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $294.26 | 2021-2024 | |
| Currax Pharmaceuticals LLC | $255.20 | 2021-2023 | Nexlizet, Contrave, Nexletol |
| Kowa Pharmaceuticals America, INC. | $242.72 | 2021-2025 | Livalo, Zoryve |
| Janssen Pharmaceuticals, INC | $191.15 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $166.86 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $160.36 | 2021-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Medtronic, INC. | $143.19 | 2023 | Nuvent |
| Novartis Pharmaceuticals Corporation | $140.54 | 2021-2023 | |
| Amgen INC. | $118.60 | 2021-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $116.44 | 2023-2024 | Veozah |
| Abbvie INC. | $92.23 | 2021-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $77.57 | 2021-2022 | |
| Esperion Therapeutics, INC. | $69.83 | 2021-2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $61.50 | 2022-2023 | Quviviq |
| Boston Scientific Corporation | $59.43 | 2023 | Watchman Access System |
| Abbott Laboratories | $48.48 | 2021-2023 | Freestyle Libre 2 |
| Eisai INC. | $46.49 | 2024 | |
| Allergan, INC. | $40.11 | 2021-2022 | |
| Exact Sciences Corporation | $38.28 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Inspire Medical Systems, INC. | $24.62 | 2025 | Inspire |
| Merz North America, INC. | $20.73 | 2021 | |
| Nevro Corp. | $20.06 | 2023 | Senza |
| Sanofi Pasteur INC. | $17.17 | 2023 | |
| Alnylam Pharmaceuticals INC. | $12.87 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Baratta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.